Population pharmacokinetic modeling and simulations of berotralstat for prophylactic treatment of attacks of hereditary angioedema.


Journal

Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067

Informations de publication

Date de publication:
04 2022
Historique:
revised: 13 12 2021
received: 15 09 2021
accepted: 19 12 2021
pubmed: 26 2 2022
medline: 19 4 2022
entrez: 25 2 2022
Statut: ppublish

Résumé

Hereditary angioedema (HAE) is an autosomal dominant disorder characterized by recurrent episodes of swelling of the skin, larynx, gastrointestinal tract, genitals, and extremities that can be disruptive to patient quality of life. Dysregulation of plasma kallikrein activity leads to increased production and accumulation of bradykinin in HAE and causes attacks of angioedema. Plasma kallikrein is a serine protease essential for the formation of bradykinin. Berotralstat is a potent, highly selective, orally bioavailable small-molecule plasma kallikrein inhibitor that has been approved to prevent attacks of HAE in adults and children 12 years of age and older. Population pharmacokinetic (PK) analyses were conducted to describe the PK of berotralstat (BCX7353; Orladeyo

Identifiants

pubmed: 35212456
doi: 10.1111/cts.13233
pmc: PMC9010267
doi:

Substances chimiques

Pyrazoles 0
Plasma Kallikrein EC 3.4.21.34
Bradykinin S8TIM42R2W
berotralstat XZA0KB1BDQ

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1027-1035

Informations de copyright

© 2022 BioCryst Pharmaceuticals, Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Références

J Allergy Clin Immunol Pract. 2021 Jan;9(1):132-150.e3
pubmed: 32898710
J Allergy Clin Immunol. 2021 Jul;148(1):164-172.e9
pubmed: 33098856
Allergy. 2021 Jun;76(6):1789-1799
pubmed: 33247955
N Engl J Med. 2018 Jul 26;379(4):352-362
pubmed: 30044938
Immunol Allergy Clin North Am. 2017 Aug;37(3):513-525
pubmed: 28687106
Clin Transl Sci. 2022 Apr;15(4):1027-1035
pubmed: 35212456
Immunotherapy. 2019 Dec;11(17):1439-1444
pubmed: 31635497
J Acquir Immune Defic Syndr. 1999 Jul 1;21(3):228-35
pubmed: 10421247
Ann Allergy Asthma Immunol. 2010 Mar;104(3):193-204
pubmed: 20377108
J Thromb Haemost. 2018 Sep;16(9):1674-1685
pubmed: 29920929
Proc Natl Acad Sci U S A. 1976 Nov;73(11):4179-83
pubmed: 1069308
Lancet. 2012 Feb 4;379(9814):474-81
pubmed: 22305226
Clin Rev Allergy Immunol. 2016 Oct;51(2):216-29
pubmed: 27459852
Allergy. 2018 Aug;73(8):1575-1596
pubmed: 29318628

Auteurs

Amanda Mathis (A)

BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA.

Mark Sale (M)

Nuventra, Inc., Durham, North Carolina, USA.

Melanie Cornpropst (M)

BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA.

William P Sheridan (WP)

BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA.

Shu Chin Ma (SC)

BioCryst Pharmaceuticals, Inc., Durham, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH